The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking.
Identifieur interne : 000368 ( PubMed/Checkpoint ); précédent : 000367; suivant : 000369The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking.
Auteurs : Debra L. Kiss [Australie] ; James Longden ; Gregory A. Fechner ; Vicky M. AverySource :
- Cellular & molecular biology letters ; 2009.
English descriptors
- KwdEn :
- Animals, CCR5 Receptor Antagonists, CHO Cells, Ceramides (metabolism), Chemokine CCL3 (pharmacology), Chemokine CCL5 (pharmacology), Cricetinae, Cricetulus, Endosomes (drug effects), Endosomes (metabolism), Golgi Apparatus (metabolism), Humans, Ligands, Protein Transport, Receptors, CCR5 (agonists), Receptors, CCR5 (genetics), Receptors, CCR5 (metabolism).
- MESH :
- chemical , agonists : Receptors, CCR5.
- chemical , genetics : Receptors, CCR5.
- chemical , metabolism : Ceramides, Receptors, CCR5.
- chemical , pharmacology : Chemokine CCL3, Chemokine CCL5.
- chemical : CCR5 Receptor Antagonists, Ligands.
- drug effects : Endosomes.
- metabolism : Endosomes, Golgi Apparatus.
- Animals, CHO Cells, Cricetinae, Cricetulus, Humans, Protein Transport.
Abstract
CC chemokine receptor 5 (CCR5) is a pro-inflammatory chemokine receptor that is expressed on cells of the immune system, and specializes in cell migration in response to inflammation and tissue damage. Due to its key role in cell communication and migration, this receptor is involved in various inflammatory and autoimmune diseases, in addition to HIV infection. Met-RANTES is a modified CCR5 ligand that has previously been shown to antagonize CCR5 activation and function in response to its natural ligands in vitro. In vivo, Met-RANTES is able to reduce inflammation in models of induced inflammatory and autoimmune diseases. However, due to the fact that Met-RANTES is also capable of partial agonist activity regarding receptor signaling and internalization, it is clear that Met-RANTES does not function as a conventional receptor antagonist. To further elucidate the effect of Met-RANTES on CCR5, receptor trafficking was investigated in a CHO-CCR5-GFP cell line using the Opera confocal plate reader. The internalization response of CCR5 was quantified, and showed that Met-RANTES internalized CCR5 in a slower, less potent manner than the agonists CCL3 and CCL5. Fluorescent organelle labeling and live cell imaging showed CCL3 and CCL5 caused CCR5 to traffic through sorting endosomes, recycling endosomes and the Golgi apparatus. In contrast, Met-RANTES caused CCR5 to traffic through sorting endosomes and the Golgi apparatus in a manner that was independent of recycling endosomes. As receptor trafficking impacts on cell surface expression and the ability of the receptor to respond to more ligand, this information may indicate an alternative regulation of CCR5 by Met-RANTES that allows the modified ligand to reduce inflammation through stimulation of a pro-inflammatory receptor.
DOI: 10.2478/s11658-009-0017-1
PubMed: 19448977
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:19448977Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking.</title><author><name sortKey="Kiss, Debra L" sort="Kiss, Debra L" uniqKey="Kiss D" first="Debra L" last="Kiss">Debra L. Kiss</name><affiliation wicri:level="1"><nlm:affiliation>Discovery Biology, Eskitis Institute for Cell and Molecular Therapies, Brisbane Innovation Park, Griffith University, Don Young Road, Nathan, QLD, 4111, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Discovery Biology, Eskitis Institute for Cell and Molecular Therapies, Brisbane Innovation Park, Griffith University, Don Young Road, Nathan, QLD, 4111</wicri:regionArea><wicri:noRegion>4111</wicri:noRegion></affiliation></author><author><name sortKey="Longden, James" sort="Longden, James" uniqKey="Longden J" first="James" last="Longden">James Longden</name></author><author><name sortKey="Fechner, Gregory A" sort="Fechner, Gregory A" uniqKey="Fechner G" first="Gregory A" last="Fechner">Gregory A. Fechner</name></author><author><name sortKey="Avery, Vicky M" sort="Avery, Vicky M" uniqKey="Avery V" first="Vicky M" last="Avery">Vicky M. Avery</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.2478/s11658-009-0017-1</idno><idno type="RBID">pubmed:19448977</idno><idno type="pmid">19448977</idno><idno type="wicri:Area/PubMed/Corpus">000389</idno><idno type="wicri:Area/PubMed/Curation">000389</idno><idno type="wicri:Area/PubMed/Checkpoint">000368</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking.</title><author><name sortKey="Kiss, Debra L" sort="Kiss, Debra L" uniqKey="Kiss D" first="Debra L" last="Kiss">Debra L. Kiss</name><affiliation wicri:level="1"><nlm:affiliation>Discovery Biology, Eskitis Institute for Cell and Molecular Therapies, Brisbane Innovation Park, Griffith University, Don Young Road, Nathan, QLD, 4111, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Discovery Biology, Eskitis Institute for Cell and Molecular Therapies, Brisbane Innovation Park, Griffith University, Don Young Road, Nathan, QLD, 4111</wicri:regionArea><wicri:noRegion>4111</wicri:noRegion></affiliation></author><author><name sortKey="Longden, James" sort="Longden, James" uniqKey="Longden J" first="James" last="Longden">James Longden</name></author><author><name sortKey="Fechner, Gregory A" sort="Fechner, Gregory A" uniqKey="Fechner G" first="Gregory A" last="Fechner">Gregory A. Fechner</name></author><author><name sortKey="Avery, Vicky M" sort="Avery, Vicky M" uniqKey="Avery V" first="Vicky M" last="Avery">Vicky M. Avery</name></author></analytic><series><title level="j">Cellular & molecular biology letters</title><idno type="e-ISSN">1689-1392</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>CCR5 Receptor Antagonists</term><term>CHO Cells</term><term>Ceramides (metabolism)</term><term>Chemokine CCL3 (pharmacology)</term><term>Chemokine CCL5 (pharmacology)</term><term>Cricetinae</term><term>Cricetulus</term><term>Endosomes (drug effects)</term><term>Endosomes (metabolism)</term><term>Golgi Apparatus (metabolism)</term><term>Humans</term><term>Ligands</term><term>Protein Transport</term><term>Receptors, CCR5 (agonists)</term><term>Receptors, CCR5 (genetics)</term><term>Receptors, CCR5 (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Receptors, CCR5</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Receptors, CCR5</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Ceramides</term><term>Receptors, CCR5</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Chemokine CCL3</term><term>Chemokine CCL5</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>CCR5 Receptor Antagonists</term><term>Ligands</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Endosomes</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Endosomes</term><term>Golgi Apparatus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>CHO Cells</term><term>Cricetinae</term><term>Cricetulus</term><term>Humans</term><term>Protein Transport</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">CC chemokine receptor 5 (CCR5) is a pro-inflammatory chemokine receptor that is expressed on cells of the immune system, and specializes in cell migration in response to inflammation and tissue damage. Due to its key role in cell communication and migration, this receptor is involved in various inflammatory and autoimmune diseases, in addition to HIV infection. Met-RANTES is a modified CCR5 ligand that has previously been shown to antagonize CCR5 activation and function in response to its natural ligands in vitro. In vivo, Met-RANTES is able to reduce inflammation in models of induced inflammatory and autoimmune diseases. However, due to the fact that Met-RANTES is also capable of partial agonist activity regarding receptor signaling and internalization, it is clear that Met-RANTES does not function as a conventional receptor antagonist. To further elucidate the effect of Met-RANTES on CCR5, receptor trafficking was investigated in a CHO-CCR5-GFP cell line using the Opera confocal plate reader. The internalization response of CCR5 was quantified, and showed that Met-RANTES internalized CCR5 in a slower, less potent manner than the agonists CCL3 and CCL5. Fluorescent organelle labeling and live cell imaging showed CCL3 and CCL5 caused CCR5 to traffic through sorting endosomes, recycling endosomes and the Golgi apparatus. In contrast, Met-RANTES caused CCR5 to traffic through sorting endosomes and the Golgi apparatus in a manner that was independent of recycling endosomes. As receptor trafficking impacts on cell surface expression and the ability of the receptor to respond to more ligand, this information may indicate an alternative regulation of CCR5 by Met-RANTES that allows the modified ligand to reduce inflammation through stimulation of a pro-inflammatory receptor.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19448977</PMID><DateCreated><Year>2009</Year><Month>09</Month><Day>18</Day></DateCreated><DateCompleted><Year>2009</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1689-1392</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Cellular & molecular biology letters</Title><ISOAbbreviation>Cell. Mol. Biol. Lett.</ISOAbbreviation></Journal><ArticleTitle>The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking.</ArticleTitle><Pagination><MedlinePgn>537-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2478/s11658-009-0017-1</ELocationID><Abstract><AbstractText>CC chemokine receptor 5 (CCR5) is a pro-inflammatory chemokine receptor that is expressed on cells of the immune system, and specializes in cell migration in response to inflammation and tissue damage. Due to its key role in cell communication and migration, this receptor is involved in various inflammatory and autoimmune diseases, in addition to HIV infection. Met-RANTES is a modified CCR5 ligand that has previously been shown to antagonize CCR5 activation and function in response to its natural ligands in vitro. In vivo, Met-RANTES is able to reduce inflammation in models of induced inflammatory and autoimmune diseases. However, due to the fact that Met-RANTES is also capable of partial agonist activity regarding receptor signaling and internalization, it is clear that Met-RANTES does not function as a conventional receptor antagonist. To further elucidate the effect of Met-RANTES on CCR5, receptor trafficking was investigated in a CHO-CCR5-GFP cell line using the Opera confocal plate reader. The internalization response of CCR5 was quantified, and showed that Met-RANTES internalized CCR5 in a slower, less potent manner than the agonists CCL3 and CCL5. Fluorescent organelle labeling and live cell imaging showed CCL3 and CCL5 caused CCR5 to traffic through sorting endosomes, recycling endosomes and the Golgi apparatus. In contrast, Met-RANTES caused CCR5 to traffic through sorting endosomes and the Golgi apparatus in a manner that was independent of recycling endosomes. As receptor trafficking impacts on cell surface expression and the ability of the receptor to respond to more ligand, this information may indicate an alternative regulation of CCR5 by Met-RANTES that allows the modified ligand to reduce inflammation through stimulation of a pro-inflammatory receptor.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kiss</LastName><ForeName>Debra L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Discovery Biology, Eskitis Institute for Cell and Molecular Therapies, Brisbane Innovation Park, Griffith University, Don Young Road, Nathan, QLD, 4111, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longden</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Fechner</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Avery</LastName><ForeName>Vicky M</ForeName><Initials>VM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Cell Mol Biol Lett</MedlineTA><NlmUniqueID>9607427</NlmUniqueID><ISSNLinking>1425-8153</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065100">CCR5 Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002518">Ceramides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054405">Chemokine CCL3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018946">Chemokine CCL5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C108335">RANTES, Met-</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019713">Receptors, CCR5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D065100">CCR5 Receptor Antagonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016466">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002518">Ceramides</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D054405">Chemokine CCL3</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018946">Chemokine CCL5</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006224">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003412">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011992">Endosomes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006056">Golgi Apparatus</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008024">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D021381">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019713">Receptors, CCR5</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000819">agonists</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2009</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.2478/s11658-009-0017-1</ArticleId><ArticleId IdType="pubmed">19448977</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li></country></list><tree><noCountry><name sortKey="Avery, Vicky M" sort="Avery, Vicky M" uniqKey="Avery V" first="Vicky M" last="Avery">Vicky M. Avery</name><name sortKey="Fechner, Gregory A" sort="Fechner, Gregory A" uniqKey="Fechner G" first="Gregory A" last="Fechner">Gregory A. Fechner</name><name sortKey="Longden, James" sort="Longden, James" uniqKey="Longden J" first="James" last="Longden">James Longden</name></noCountry><country name="Australie"><noRegion><name sortKey="Kiss, Debra L" sort="Kiss, Debra L" uniqKey="Kiss D" first="Debra L" last="Kiss">Debra L. Kiss</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000368 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000368 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= OperaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:19448977
|texte= The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:19448977" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a OperaV1
| This area was generated with Dilib version V0.6.21. |  |